Publications

Found 29 results
Filters: Author is Poignard, Pascal  [Clear All Filters]
2012
Ota T, Doyle-Cooper C, Cooper AB, Huber M, Falkowska E, Doores KJ, Hangartner L, Le K, Sok D, Jardine J et al..  2012.  Anti-HIV B Cell lines as candidate vaccine biosensors.. J Immunol. 189(10):4816-24.
Klein F, Gaebler C, Mouquet H, Sather ND, Lehmann C, Scheid JF, Kraft Z, Liu Y, Pietzsch J, Hurley A et al..  2012.  Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein.. J Exp Med. 209(8):1469-79.
Burton DR, Poignard P, Stanfield RL, Wilson IA.  2012.  Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses.. Science. 337(6091):183-6.
Moldt B, Rakasz EG, Schultz N, Chan-Hui P-Y, Swiderek K, Weisgrau KL, Piaskowski SM, Bergman Z, Watkins DI, Poignard P et al..  2012.  Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.. Proc Natl Acad Sci U S A. 109(46):18921-5.
Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop CD, Finstad SL, Jin C, Landucci G, Alpert MD et al..  2012.  A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.. J Virol. 86(11):6189-96.
Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker LM, Wu X, Seaman MS, Wrin T, Kwong PD et al..  2012.  PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.. J Virol. 86(8):4394-403.

Pages